| abstract |
Use of nucleoside derivatives of formula (I) wherein R1 and R2 are independently selected from hydrogen and C18- and C20-saturated and mono-unsaturated acyl groups, provided that R1 and R2 may not be both hydrogen, for the manufacture of a pharmaceutical composition for the treatment of solid tumors and lymphons. Further disclosed are nucleoside derivatives of formula (I) wherein R 1 and R 2 are independently selected from hydrogen, elaidoyl, oleoyl, stearoyl, eicosenoyl (cis or trans) and eicosanoyl, provided that the radicals R 1 and R 2 may not both contain hydrogen, oleoyl, elaidoyl, stearoyl or eicosanoyl, R1 may not be hydrogen if R2 is oleoyl or stearoyl and R2 may not be hydrogen if R1 is elaidoyl, oleoyl, stearoyl or eicosanoyl, and pharmaceutical preparations containing them. |